FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783640123> ?p ?o ?g. }

• W2783640123 endingPage "991" @default.
• W2783640123 startingPage "985" @default.
• W2783640123 abstract "To investigate the activity and safety of afatinib in the preoperative treatment of squamous cell carcinoma of the head and neck (SCCHN).This study was an open-label, randomized, multicenter, phase II window of opportunity trial. Treatment-naïve SCCHN patients selected for primary curative surgery were randomized (5 : 1 ratio) to receive afatinib during 14 days (day -15 until day -1) before surgery (day 0) or no treatment. Tumor biopsies, 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET), and magnetic resonance imaging (MRI) were carried out at diagnosis and just before surgery. The primary end point was metabolic FDG-PET response (according to EORTC guidelines). Other end points included response assessment based on the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, dynamic contrast-enhanced (DCE)-MRI, diffusion weighted (DW)-MRI, safety, and translational research (TR).Thirty patients were randomized: 25 to afatinib and 5 to control arm. Of the 23 eligible patients randomized to afatinib, 16 (70%; 95% CI: 47% to 87%) patients had a partial metabolic FDG-PET response (PMR). Five patients (22%; 95% CI: 8% to 44%) showed a partial response by RECISTv1.1. Responses assessed via DCE-MRI and DWI-MRI did not show a strong association with PMR or RECIST. One patient discontinued afatinib after 11 days for grade 3 diarrhea with subsequent renal failure and 24 days delay in surgery. No grade 4 toxicities or surgical comorbidities related to afatinib were reported. TR results indicated that PMR was more frequent in the tumors with high Cluster3-hypoxia score expression and with TP53 wild type.Afatinib given for 2 weeks to newly diagnosed SCCHN patients induces a high rate of FDG-PET partial metabolic response and partial response according to RECISTv1.1. Afatinib can be safely administered before surgery. Although exploratory, the hypoxic gene signature needs further investigations as a predictive biomarker of afatinib activity.ClinicalTrials.gov: NCT01538381." @default.
• W2783640123 created "2018-01-26" @default.
• W2783640123 creator A5001037498 @default.
• W2783640123 creator A5011885579 @default.
• W2783640123 creator A5017363293 @default.
• W2783640123 creator A5018624121 @default.
• W2783640123 creator A5019150229 @default.
• W2783640123 creator A5019926045 @default.
• W2783640123 creator A5022860546 @default.
• W2783640123 creator A5028429315 @default.
• W2783640123 creator A5029221114 @default.
• W2783640123 creator A5034267169 @default.
• W2783640123 creator A5037526893 @default.
• W2783640123 creator A5039048580 @default.
• W2783640123 creator A5040310081 @default.
• W2783640123 creator A5041771868 @default.
• W2783640123 creator A5047193688 @default.
• W2783640123 creator A5049853731 @default.
• W2783640123 creator A5050884991 @default.
• W2783640123 creator A5057318573 @default.
• W2783640123 creator A5061225830 @default.
• W2783640123 creator A5072176034 @default.
• W2783640123 creator A5073023506 @default.
• W2783640123 creator A5074118140 @default.
• W2783640123 creator A5085847320 @default.
• W2783640123 date "2018-04-01" @default.
• W2783640123 modified "2023-10-17" @default.
• W2783640123 title "Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)" @default.
• W2783640123 cites W1953192109 @default.
• W2783640123 cites W1971142107 @default.
• W2783640123 cites W1998417857 @default.
• W2783640123 cites W2019607817 @default.
• W2783640123 cites W2108549165 @default.
• W2783640123 cites W2112845420 @default.
• W2783640123 cites W2125486087 @default.
• W2783640123 cites W2132087081 @default.
• W2783640123 cites W2145938281 @default.
• W2783640123 cites W2155384808 @default.
• W2783640123 cites W2161235207 @default.
• W2783640123 cites W2163186602 @default.
• W2783640123 cites W2165303797 @default.
• W2783640123 cites W2183740920 @default.
• W2783640123 cites W2281165738 @default.
• W2783640123 cites W2735625431 @default.
• W2783640123 cites W2891705592 @default.
• W2783640123 doi "https://doi.org/10.1093/annonc/mdy013" @default.
• W2783640123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29346507" @default.
• W2783640123 hasPublicationYear "2018" @default.
• W2783640123 type Work @default.
• W2783640123 sameAs 2783640123 @default.
• W2783640123 citedByCount "31" @default.
• W2783640123 countsByYear W27836401232018 @default.
• W2783640123 countsByYear W27836401232019 @default.
• W2783640123 countsByYear W27836401232020 @default.
• W2783640123 countsByYear W27836401232021 @default.
• W2783640123 countsByYear W27836401232022 @default.
• W2783640123 countsByYear W27836401232023 @default.
• W2783640123 crossrefType "journal-article" @default.
• W2783640123 hasAuthorship W2783640123A5001037498 @default.
• W2783640123 hasAuthorship W2783640123A5011885579 @default.
• W2783640123 hasAuthorship W2783640123A5017363293 @default.
• W2783640123 hasAuthorship W2783640123A5018624121 @default.
• W2783640123 hasAuthorship W2783640123A5019150229 @default.
• W2783640123 hasAuthorship W2783640123A5019926045 @default.
• W2783640123 hasAuthorship W2783640123A5022860546 @default.
• W2783640123 hasAuthorship W2783640123A5028429315 @default.
• W2783640123 hasAuthorship W2783640123A5029221114 @default.
• W2783640123 hasAuthorship W2783640123A5034267169 @default.
• W2783640123 hasAuthorship W2783640123A5037526893 @default.
• W2783640123 hasAuthorship W2783640123A5039048580 @default.
• W2783640123 hasAuthorship W2783640123A5040310081 @default.
• W2783640123 hasAuthorship W2783640123A5041771868 @default.
• W2783640123 hasAuthorship W2783640123A5047193688 @default.
• W2783640123 hasAuthorship W2783640123A5049853731 @default.
• W2783640123 hasAuthorship W2783640123A5050884991 @default.
• W2783640123 hasAuthorship W2783640123A5057318573 @default.
• W2783640123 hasAuthorship W2783640123A5061225830 @default.
• W2783640123 hasAuthorship W2783640123A5072176034 @default.
• W2783640123 hasAuthorship W2783640123A5073023506 @default.
• W2783640123 hasAuthorship W2783640123A5074118140 @default.
• W2783640123 hasAuthorship W2783640123A5085847320 @default.
• W2783640123 hasBestOaLocation W27836401231 @default.
• W2783640123 hasConcept C121608353 @default.
• W2783640123 hasConcept C126322002 @default.
• W2783640123 hasConcept C126838900 @default.
• W2783640123 hasConcept C141071460 @default.
• W2783640123 hasConcept C143409427 @default.
• W2783640123 hasConcept C143998085 @default.
• W2783640123 hasConcept C168563851 @default.
• W2783640123 hasConcept C203092338 @default.
• W2783640123 hasConcept C2775842073 @default.
• W2783640123 hasConcept C2778087573 @default.
• W2783640123 hasConcept C2779438470 @default.
• W2783640123 hasConcept C2779984678 @default.
• W2783640123 hasConcept C2780586478 @default.
• W2783640123 hasConcept C31760486 @default.
• W2783640123 hasConcept C535046627 @default.
• W2783640123 hasConcept C71924100 @default.

• next